TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals (NASDAQ:ABPI) -- Television stations across the country recently interviewed Dr. David Sherris, co-inventor of SinuNase™ and Chairman of the University of Buffalo Department of Otolaryngology, about the diagnosis and treatment of chronic sinusitis, and the extensive research conducted at the Mayo Clinic that identified a fungal origin of the disease. These interviews are part of Accentia’s ongoing public education program to address the extensive research that has shown a fungal etiology related to chronic sinusitis, a disease that affects over 31 million Americans, and the proposed approach to treat the disease with a very low dose of an antifungal in an intranasal formulation.
